We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim has announced acceptance of a biologics license application (BLA) and granting of priority review by the US Food and Drug Administration (FDA) for spesolimab in treating generalized pustular psoriasis (GPP) flares.